Aurobindo Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.68×	0.69×	0.68×	0.72×	0.73×
	1.04×	1.01×	1.03×	1.02×	1.06×
	15.0%	15.1%	15.6%	14.9%	10.0%
	0.62×	0.62×	0.67×	0.68×	0.67×
	1.54×	1.54×	1.52×	1.51×	1.49×
	10.2%	10.0%	11.2%	11.2%	7.7%
	9.9%	9.9%	11.2%	11.2%	7.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AUROPHARMA₹1,659.90

Aurobindo Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY CIPLA FORTIS LUPIN ALKEM LAURUSLABS MANKINDMcap ₹96,407 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.73	0.72	0.68	0.69	0.68
Interest Burden (Pretax/EBIT) ×	1.06	1.02	1.03	1.01	1.04
EBIT Margin %	9.95	14.90	15.55	15.06	14.96
Asset Turnover ×	0.67	0.68	0.67	0.62	0.62
Financial Leverage (Assets/Equity) ×	1.49	1.51	1.52	1.54	1.54
ROE (5-step product, year-end total equity) %	7.72	11.22	11.22	9.97	10.17
ROE (owners' profit / average owners' equity) %	7.50	11.20	11.16	9.94	9.94

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.